ASX ANNOUNCEMENT 16 November 2026 Radiopharm Theranostics Presents Interim Analysis from Phase 2b Imaging Study of RAD101 in Suspected Recurrent Brain Metastases Following Radiotherapy at the Society for Neuro-Oncology Annual Meeting 18 Concordance between F-RAD101 PET and contrast-enhanced MRI...
RAD interim analysis at SNO26 on RAD101 Phase IIb data
Filed with ASX · · 3 pages · English
Release
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Change of Director's Interest Notices x 4
- RAD Alignment with US FDA for Development of RAD101
- Quarterly Activities/Appendix 4C Cash Flow Report
- Notice of Annual General Meeting/Proxy Form
- Radiopharm receives $8M advance on FY26 R&D tax incentive
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics